In patient samples, STK11 function is often altered either by inactivating point mutations, reduced gene expression or chromosomal loss in 4–34% of tested human adenocarcinomas of the lung, with the percentage of somatic mutations being described as lowest in Asian cohorts and highest in Caucasians [13,49,50,51,52]. This evidence concerns the gene STK11 and lung adenocarcinoma.